Matinas Biopharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

To all sites on hold, we appreciate your patience and please continue to stand by. Thank you. Please stand by. Your program is about to begin. Welcome to the Matinus Biopharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press the star key followed by the number 1 on your touchtone phone. If anyone has difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this conference is being recorded. I would now like to turn the conference over to Jody Kane. Please go ahead. This is Jody Kane with LHA Investor Relations. Thank you for participating in today's call. Joining me from Martinez Biopharma are Jerry Jabbour, Chief Executive Officer of Dr. Terry Matkovic, Chief Development Officer, Dr. Terry Ferguson, Chief Medical Officer, and Keith Katynski, Chief Financial Officer. Tom Hoover, the company's Chief Business Officer, will be available to answer questions during the Q&A session. I'd like to remind listeners that remarks made during this call may state management's future intentions, hopes, beliefs, expectations, and projections. These are forward-looking statements that involve risks and uncertainties. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are based on Matinus Biopharma's current expectations, and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discu...